On October 27, CSPC PHARMA fell 3.04% in Regular Trading, trading at HK$7.98, with turnover of HK$292 million.

The latest catalyst in focus was the company’s disclosure of interim Phase III data for anbenitamab combined with albumin-bound docetaxel as first-line treatment for HER2-positive advanced breast cancer. The study showed a 54% reduction in the risk of disease progression or death, with a 24-month progression-free survival rate of 58.5% versus 34.4% for the standard-treatment group.

Despite the positive clinical update, the Pharmaceuticals sector was broadly under pressure on October 27, limiting support for the shares. Peer moves included SBP GROUP falling 2.14%, HANSOH PHARMA falling 3.10%, HENGRUI PHARMA falling 4.50%, HUTCHMED falling 5.59%, and ASYMCHEM falling 4.71%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)